Heron Therapeutics, Inc.
Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Last updated:
Abstract:
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Status:
Grant
Type:
Utility
Filling date:
16 Mar 2020
Issue date:
16 Nov 2021